Obesity Statistics: Prevalence, Health Risks, and Trends

41.9% of US adults aged 20+ had obesity (BMI ≥30) in 2017-March 2020

Prevalence has roughly doubled since 1990. Severe obesity (BMI ≥40) affects 9.2% of US adults, also rising sharply.

73.6% of US adults are either overweight or obese (BMI ≥25)

Combined prevalence is the most cited population-health threshold. Tracked via biennial NHANES sampling rounds.

Annual US medical costs attributable to obesity reached $260.6 billion in 2016

Adults with obesity face annual medical costs roughly $2,500 (100%) higher than normal-weight adults, rising to 233% higher with class III obesity (BMI ≥40).

Obesity raises type 2 diabetes risk by 3-7x compared to healthy-weight adults

Class III obesity (BMI ≥40) is associated with even higher diabetes incidence — roughly 7x. Risk drops measurably with 5-10% weight loss.

Global adult obesity prevalence more than doubled from 1990 to 2022

Global obesity rose from 7% (1990) to 16% (2022) in adults. Childhood obesity rose from 2% to 8% over the same period.

Obesity is associated with at least 13 different types of cancer

Includes esophageal, gastric, colorectal, liver, gallbladder, pancreatic, kidney, breast (postmenopausal), endometrial, ovarian, thyroid cancers, multiple myeloma, and meningioma.

Class II/III obesity (BMI ≥35) reduces life expectancy by 8-10 years

Pooled analysis of 57 prospective studies (894,576 participants). Mortality risk rises ~30% per 5 BMI units above 25.

Bariatric surgery produces 25-30% sustained body-weight loss at 5 years

Far above the 5-10% sustained loss typical of diet-and-lifestyle interventions. Roux-en-Y produces slightly larger long-term loss than sleeve gastrectomy.

GLP-1 receptor agonists (semaglutide 2.4 mg) produce ~15% mean body-weight loss at 68 weeks

Effect size is approximately double earlier obesity drugs. Loss is largely preserved with continued treatment but partially regained on cessation.

Sustained 5-10% body-weight loss reduces type 2 diabetes incidence by ~58% in pre-diabetic adults

Lifestyle intervention outperformed metformin (31% reduction). Translates to ~7 lb sustained loss in a 150 lb person.

Visceral (abdominal) fat is more strongly linked to cardiometabolic risk than total body fat

Waist circumference >102 cm (men) or >88 cm (women) signals elevated risk independent of BMI. CT and DEXA quantify visceral mass directly.

Adults with obesity who maintain 30+ minutes of moderate activity daily have mortality risk approaching healthy-weight sedentary adults

EPIC cohort of 334,161 European adults. Physical inactivity is associated with twice as many deaths as obesity.

Childhood obesity prevalence in the US is approximately 19.7%, affecting 14.7 million children and adolescents

Obesity prevalence among US children aged 2-19 has roughly tripled since the 1970s. Disparities are large by race/ethnicity and household income.

BMI ≥30 is associated with a ~20% increase in all-cause mortality compared to BMI 22.5-25

Pooled analysis of 239 prospective studies (10.6 million participants). Risk rises sharply above BMI 30; modest excess weight (BMI 25-27) shows minimal mortality difference in non-smokers.

Tirzepatide (15 mg weekly) produced ~21% mean body-weight loss at 72 weeks in adults with obesity

Dual GIP/GLP-1 agonist. Effect size is ~50% larger than semaglutide alone. Approved as Zepbound for chronic weight management.